JP7037486B2 - 医薬としてのヒト由来免疫抑制タンパク質およびペプチドの使用 - Google Patents

医薬としてのヒト由来免疫抑制タンパク質およびペプチドの使用 Download PDF

Info

Publication number
JP7037486B2
JP7037486B2 JP2018536331A JP2018536331A JP7037486B2 JP 7037486 B2 JP7037486 B2 JP 7037486B2 JP 2018536331 A JP2018536331 A JP 2018536331A JP 2018536331 A JP2018536331 A JP 2018536331A JP 7037486 B2 JP7037486 B2 JP 7037486B2
Authority
JP
Japan
Prior art keywords
disease
polypeptide
protein
syndrome
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018536331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533974A5 (enExample
JP2018533974A (ja
Inventor
マウダリーナ・ヤニーナ・ラスカ
アン・マルグレーテ・トロルボー
クリスティアン・ステンゴー－ペデルセン
シェルヴィン・バーラミ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aimvion AS
Original Assignee
Aimvion AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimvion AS filed Critical Aimvion AS
Publication of JP2018533974A publication Critical patent/JP2018533974A/ja
Publication of JP2018533974A5 publication Critical patent/JP2018533974A5/ja
Application granted granted Critical
Publication of JP7037486B2 publication Critical patent/JP7037486B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018536331A 2015-10-01 2016-09-30 医薬としてのヒト由来免疫抑制タンパク質およびペプチドの使用 Expired - Fee Related JP7037486B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201570620 2015-10-01
DKPA201570620 2015-10-01
DKPA201670634 2016-08-23
DKPA201670634 2016-08-23
PCT/DK2016/050316 WO2017054831A1 (en) 2015-10-01 2016-09-30 Use of human derived immunosuppressive proteins and peptides as medicaments

Publications (3)

Publication Number Publication Date
JP2018533974A JP2018533974A (ja) 2018-11-22
JP2018533974A5 JP2018533974A5 (enExample) 2019-10-03
JP7037486B2 true JP7037486B2 (ja) 2022-03-16

Family

ID=57144698

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536331A Expired - Fee Related JP7037486B2 (ja) 2015-10-01 2016-09-30 医薬としてのヒト由来免疫抑制タンパク質およびペプチドの使用

Country Status (6)

Country Link
US (1) US20190040106A1 (enExample)
EP (1) EP3356389A1 (enExample)
JP (1) JP7037486B2 (enExample)
CN (1) CN108368155A (enExample)
CA (1) CA2999792A1 (enExample)
WO (1) WO2017054831A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528071A (ja) * 2016-08-23 2019-10-10 エイムヴィオン・アクティエセルスカブＡｉｍＶｉｏｎ Ａ／Ｓ 新規免疫刺激ペプチド
JP7277466B2 (ja) * 2017-09-01 2023-05-19 インプラザー エー・ペー・エス 疾患の予防および／または治療における使用のためのワクチン
US11352421B2 (en) 2018-12-11 2022-06-07 Rush University Medical Center Treatment for adverse immune reaction to metal implant debris

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087748A1 (en) 2003-04-04 2004-10-14 Centre National De La Recherche Scientifique Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same
WO2009106073A2 (en) 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048763A1 (en) * 2000-02-04 2002-04-25 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis
WO2005095442A1 (en) * 2004-03-30 2005-10-13 Institut Gustave Roussy Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087748A1 (en) 2003-04-04 2004-10-14 Centre National De La Recherche Scientifique Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same
WO2009106073A2 (en) 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding

Also Published As

Publication number Publication date
JP2018533974A (ja) 2018-11-22
CA2999792A1 (en) 2017-04-06
CN108368155A (zh) 2018-08-03
US20190040106A1 (en) 2019-02-07
EP3356389A1 (en) 2018-08-08
WO2017054831A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
KR101997757B1 (ko) 악액질 예방 또는 치료용 조성물
JP6671069B2 (ja) 炎症性疾患の予防又は治療剤
JP7037486B2 (ja) 医薬としてのヒト由来免疫抑制タンパク質およびペプチドの使用
US20140288010A1 (en) Compositions and Methods for Increasing Stem Cell Survival
BR112019014406A2 (pt) métodos de tratar esclerose múltipla usando células t autólogas
GB2526898A (en) Biological materials and therapeutic uses thereof
US20240207377A1 (en) Alpha-1-antitrypsin (aat) in the treatment and/or prevention of neurological disorders
CN113015746A (zh) 在类风湿性关节炎中的ptprs和蛋白聚糖
CN112243380A (zh) 用于治疗自身免疫性疾病的方法
WO2021228052A1 (zh) 生物大分子靶向特异性补体抑制剂及其制备方法与应用
EP2983706B1 (en) Use of immune suppressive domains as medicaments
CA2596842A1 (en) Synthetic peptide copolymers for treatment and prevention of cardiovascular disorders
US20140170108A1 (en) Compositions useful for the treatment of inflammatory disease or disorders
US8076293B2 (en) Use of BiP or a variant, homologue, derivative or fragment thereof in the manufacture of a medicament for the prevention or treatment of bone loss or bone resorption
JP7570324B2 (ja) 抗炎症特性を有する新規タンパク質
WO2021219896A1 (en) Treatment and/or prevention of a disease or a syndrome related to a virus infection
Rodríguez et al. Type I interferons regulate nitric oxide production in Brucella abortus-activated microglia contributing to neuronal death
RU2840475C2 (ru) Альфа-1-антитрипсин (ААТ) в лечении и (или) профилактике неврологических нарушений
WO2024145365A2 (en) Compositions for the diagnosis, treatment, prevention, and alleviation of neurodegenerative and autoimmune disorders
US20230302104A1 (en) Treatment and/or prevention of a disease or a syndrome related to a virus infection
Jeong et al. Different strategies for producing naturally soluble form of common cytokine receptor γ chain
WO2024061239A1 (zh) 用于预防或治疗冠状病毒感染的融合蛋白、Spike蛋白纳米颗粒及其应用
WO2021209636A1 (en) 28 kda gst proteins from schistosoma for the treatment of vasculitis
Center 2050-084X
WO2005068497A1 (en) Iis: a novel ifn-gamma-inducible protein, member of the secretoglobin family, that modulates cellular invasion and migration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220304

R150 Certificate of patent or registration of utility model

Ref document number: 7037486

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees